Previous Close | 6.43 |
Open | 6.58 |
Bid | 0.00 x 2900 |
Ask | 0.00 x 1800 |
Day's Range | 6.47 - 7.36 |
52 Week Range | 5.31 - 46.91 |
Volume | |
Avg. Volume | 834,086 |
Market Cap | 605.819M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 23.37 |
EPS (TTM) | 0.31 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.50 |
From what we can see, insiders were net buyers in Atea Pharmaceuticals, Inc.'s ( NASDAQ:AVIR ) during the past 12...
Image source: The Motley Fool. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)Q1 2022 Earnings CallMay 10, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the Atea Pharmaceuticals first quarter 2022 earnings conference call.
New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical results from final analysis of Phase 2 hospitalized study in high-risk COVID-19 patients suggest potential clinical benefits with bemnifosbuvir versus placebo New in vitro results demonstrate bemnifosbuvir retains antiviral activity against all SARS-CoV-2